

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED: <i>Memorial Hospital South Bend, IN</i>		2. NRC/REGIONAL OFFICE U.S. Nuclear Regulatory Commission Region III 2443 Warrenville Road Suite 210 Lisle, Illinois 60532-4351	
REPORT <i>2008-001</i>			
3. DOCKET NUMBER(S) <i>030-17335</i>	4. LICENSEE NUMBER(S) <i>13-18881-01</i>	5. DATE(S) OF INSPECTION <i>Feb 28, 2008</i>	

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

- 1. Based on the inspection findings, no violations were identified.
- 2. Previous violation(s) closed.
- 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.

_____ Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):

- 4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.

(Violations and Corrective Actions)

Licensee's Statement of Corrective Actions for Item 4, above.

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Deborah A. Piskura	<i>D. Piskura</i>	<i>2/28/08</i>

Docket File Information
SAFETY INSPECTION REPORT
AND COMPLIANCE INSPECTION



1. LICENSEE Memorial Hospital REPORT NUMBER(S) 2008-001	2. NRC/REGIONAL OFFICE Region III 2443 Warrenville Road Lisle, IL 60532
-------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------

3. DOCKET NUMBER(S) 030-17335	4. LICENSE NUMBER(S) 13-18881-01	5. DATE(S) OF INSPECTION Feb. 28, 2008
----------------------------------	-------------------------------------	-------------------------------------------

6. INSPECTION PROCEDURES 87130, 87131 and 87132	7. INSPECTION FOCUS AREAS 03.01, 03.02, 03.03, 03.04, 03.05, 03.06, 03.07, and 03.08
----------------------------------------------------	-----------------------------------------------------------------------------------------

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S) 02230	2. PRIORITY G 2	3. LICENSEE CONTACT Jennifer Fisher, M.S., RSO	4. TELEPHONE NUMBER 571.647.7589
-----------------------------	--------------------	---------------------------------------------------	-------------------------------------

<input checked="" type="checkbox"/> Main Office Inspection	Next Inspection Date: Feb. 2010
<input type="checkbox"/> Field	
<input type="checkbox"/> Temporary Job Site	

PROGRAM SCOPE

This licensee was a medical institution, authorized to use licensed material permitted by Sections 35.100, 35.200, 35.300, 35.400, 35.500, and 1r-192 in an HDR unit. The nuclear medicine department was staffed with four technologists who performed approximately 700-800 diagnostic nuclear medicine procedures per month. The licensee received unit doses and bulk Tc-99m from a licensed radiopharmacy. The hospital performed a full spectrum of nuclear diagnostic imaging studies. Typically, in a year, the hospital administered 20-25 iodine-131 thyroid carcinoma therapies, 50+ hyperthyroidism treatments, and 12-15 whole body CA follow up studies. The hospital obtained its I-131 in capsule form. The department administered 1-2 Sm-153 and 3-4 Y-90 dosages annually. The licensees retained the services of a consultant to audit the nuclear medicine radiation safety activities on a quarterly basis.

The radiation therapy department was staffed with 3 medical physicists, 3 dosimetrists, 8 therapy technologists, and 2 physicians (authorized users). The department used I-125 and Pd-103 for permanent prostate implants and treated approximately 25 cases per year. The oncology department possessed Cs-137 tube sources which the licensee had not used since the previous inspection. The inspector discussed disposal/transfer options of these Cs-137 sources with licensee management since the licensee expressed it would not likely resume use of these sources. The department possessed an HDR unit and administered approximately 200 patient treatments per year; the majority of these treatments were for bronchial, breast, and gynecological cancers. All HDR patient treatments were administered by the attending radiation oncologist, the medical physicist and a therapy technologists who operated the controls to the HDR unit. Source exchange, maintenance, and repairs on the HDR unit were performed by the manufacturer

This inspection consisted of interviews with selected licensee personnel, a review of selected records, tours of the nuclear medicine and radiation oncology departments, and independent measurements. The inspector observed the administration of several diagnostic nuclear medicine procedures and an I-131 hyperthyroid treatment. The inspector reviewed the written directive for the procedure and observed the patient treatment. The inspector also interviewed the physician authorized user who attended the patient. The inspection included observations of dose calibrator QA checks, HDR daily safety checks, security of byproduct material, use of personnel monitoring, and package receipts and surveys.